By Dr Kevin Chemello

Book Chapters

Jaafar A, 2023, 'Role of Proprotein Convertase Subtilisin Kexin Type 9 in Lipoprotein(a) Metabolism', in Lipoprotein(a)

Journal articles

Cochran BJ; King TW; Chemello K; Thomas SR; Rye KA, 2026, 'HDL metabolism and function in diabetes mellitus', Nature Reviews Endocrinology, 22, pp. 36 - 49, http://dx.doi.org/10.1038/s41574-025-01176-y

Jaafar AK; Paulo-Ramos A; Rastoldo G; Veeren B; Planesse C; Bringart M; Rondeau P; Chemello K; Meilhac O; Lambert GC; Bourane S, 2025, 'PCSK9 deficiency promotes the development of peripheral neuropathy.', JCI insight, pp. e183786, http://dx.doi.org/10.1172/jci.insight.183786

Chemello K; Guedon AF; Techer R; Jaafar AK; Guilhen S; Swietek MJ; Lambert G; Gallo A, 2025, 'Apolipoprotein E Plasma Concentrations Are Predictive of Recurrent Strokes: Insights From the SPARCL Trial.', Journal of the American Heart Association, 14, pp. e036630, http://dx.doi.org/10.1161/JAHA.124.036630

Chemello K; Guedon AF; Techer R; Jaafar AK; Guilhen S; Swietek MJ; Lambert G; Gallo A, 2025, 'Apolipoprotein E Plasma Concentrations Are Predictive of Recurrent Strokes: Insights From the SPARCL Trial.', Journal of the American Heart Association, 14, pp. e036630, http://dx.doi.org/10.1161/JAHA.124.036630

Chemello K; Guedon AF; Techer R; Lambert G; Gallo A, 2024, 'Apolipoprotein e concentrations are predictive of recurrent strokes: Insights from the SPARCL trial', Atherosclerosis, 395, pp. 118505 - 118505, http://dx.doi.org/10.1016/j.atherosclerosis.2024.118505

Techer R; Lambert G; Chemello K, 2024, 'GENETIC REGULATION OF LIPOPROTEIN(A) BY MICRORNAS', ATHEROSCLEROSIS, 395

Lambert G; Chemello K; Gallo A, 2023, 'Lipoprotein(a): More Than Just a Biomarker of Myocardial Fibrosis', Journal of the American College of Cardiology, 82, pp. 2292 - 2295, http://dx.doi.org/10.1016/j.jacc.2023.10.019

Chemello K; Gallo A; Guedon AF; Techer R; Croyal M; Swietek MJ; Meilhac O; Amarenco P; Lambert G, 2023, 'Lipoprotein(a): A Residual Cardiovascular Risk Factor in Statin-Treated Stroke Survivors: Insights From the SPARCL Trial', Jacc Advances, 2, http://dx.doi.org/10.1016/j.jacadv.2023.100557

Begue F; Chemello K; Veeren B; Lortat-Jacob B; Tran-Dinh A; Zappella N; Snauwaert A; Robert T; Rondeau P; Lagrange-Xelot M; Montravers P; Couret D; Tanaka S; Meilhac O, 2023, 'Plasma Apolipoprotein Concentrations Are Highly Altered in Severe Intensive Care Unit COVID-19 Patients: Preliminary Results from the LIPICOR Cohort Study', International Journal of Molecular Sciences, 24, http://dx.doi.org/10.3390/ijms24054605

Jaafar AK; Techer R; Chemello K; Lambert G; Bourane S, 2023, 'PCSK9 and the nervous system: a no-brainer?', Journal of lipid research, 64, pp. 100426, http://dx.doi.org/10.1016/j.jlr.2023.100426

Croyal M; Wargny M; Chemello K; Chevalier C; Blanchard V; Bigot-Corbel E; Lambert G; Le May C; Hadjadj S; Cariou B, 2022, 'Plasma apolipoprotein concentrations and incident diabetes in subjects with prediabetes', Cardiovascular Diabetology, 21, http://dx.doi.org/10.1186/s12933-022-01452-5

Chemello K; Gallo A; Lambert G, 2022, 'Abstract 13083: Lipoprotein(a) is a Residual Cardiovascular Risk Factor in Statin Treated Stroke Survivors - Insights From the SPARCL Trial', Circulation, 146, http://dx.doi.org/10.1161/circ.146.suppl_1.13083

Chemello K; Lambert G, 2022, 'Abstract 13135: Mir455 Targets the Repeated Domains of Lpa Open Reading Frame and Lowers Its Expression and The Secretion of Apolipoprotein (a) From Human Cells', Circulation, 146, http://dx.doi.org/10.1161/circ.146.suppl_1.13135

Chemello K; Gallo A; Lambert G, 2022, 'Lipoprotein(a) is a Residual Cardiovascular Risk Factor in Statin Treated Stroke Survivors - Insights From the SPARCL Trial', CIRCULATION, 146

Suchowerska AK; Stokman G; Palmer JT; Coghlan PA; Pieterman EJ; Keijzer N; Lambert G; Chemello K; Jaafar AK; Parmar J; Yan L; Tong Y; Mu L; Princen HMG; Bonnar J; Evison BJ, 2022, 'A Novel, Orally Bioavailable, Small-Molecule Inhibitor of PCSK9 With Significant Cholesterol-Lowering Properties In Vivo', Journal of Lipid Research, 63, http://dx.doi.org/10.1016/J.JLR.2022.100293

Chemello K; Blom DJ; Marais AD; Lambert G; Blanchard V, 2022, 'Genetic and Mechanistic Insights into the Modulation of Circulating Lipoprotein (a) Concentration by Apolipoprotein E Isoforms', Current Atherosclerosis Reports, 24, pp. 399 - 405, http://dx.doi.org/10.1007/s11883-022-01016-8

Chemello K; Chan DC; Lambert G; Watts GF, 2022, 'Recent advances in demystifying the metabolism of lipoprotein(a)', Atherosclerosis, 349, pp. 82 - 91, http://dx.doi.org/10.1016/j.atherosclerosis.2022.04.002

Blanchard V; Chemello K; Hollstein T; Hong-Fong CC; Schumann F; Grenkowitz T; Nativel B; Coassin S; Croyal M; Kassner U; Lamina C; Steinhagen-Thiessen E; Lambert G, 2022, 'The size of apolipoprotein (a) is an independent determinant of the reduction in lipoprotein (a) induced by PCSK9 inhibitors', Cardiovascular Research, 118, pp. 2103 - 2111, http://dx.doi.org/10.1093/cvr/cvab247

Coassin S; Chemello K; Khantalin I; Forer L; Döttelmayer P; Schönherr S; Grüneis R; Clément CHF; Nativel B; Stéphane RM; Gallo A; Roche M; Muelegger B; Gieger C; Peters A; Zschocke J; Marimoutou C; Meilhac O; Lamina C; Kronenberg F; Blanchard V; Lambert G, 2022, 'Genome-Wide Penetrant FormCharacterization of Hyperlipoprotein(a)emia of a Highly Associated with Genetically Elevated Cardiovascular Risk', Circulation Genomic and Precision Medicine, 15, pp. E003489, http://dx.doi.org/10.1161/CIRCGEN.121.003489

Croyal M; Wargny M; Chemello K; Chevalier C; Blanchard V; Bigot-Corbel E; Lambert G; Le May C; Hadjadj S; Cariou B, 2022, 'Plasma apolipoprotein concentrations and new-onset diabetes in subjects with prediabetes', Atherosclerosis, 355, pp. 8 - 8, http://dx.doi.org/10.1016/j.atherosclerosis.2022.06.112

Uribe KB; Chemello K; Larrea-Sebal A; Benito-Vicente A; Galicia-Garcia U; Bourane S; Jaafar AK; Lambert G; Martín C, 2021, 'A Systematic Approach to Assess the Activity and Classification of PCSK9 Variants.', International journal of molecular sciences, 22, http://dx.doi.org/10.3390/ijms222413602

Chemello K; Jaafar AK; Lambert G, 2021, 'Heart to heart with PCSK9.', European heart journal, 42, pp. 3091 - 3093, http://dx.doi.org/10.1093/eurheartj/ehab480

Huijgen R; Blom DJ; Hartgers ML; Chemello K; Benito-Vicente A; Uribe KB; Behardien Z; Blackhurst DM; Brice BC; Defesche JC; De Jong AG; Jooste RJ; Solomon GAE; Wolmarans KH; Hovingh GK; Martin C; Lambert G; Marais AD, 2021, 'Novel PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Variants in Patients With Familial Hypercholesterolemia From Cape Town', Arteriosclerosis Thrombosis and Vascular Biology, 41, pp. 934 - 943, http://dx.doi.org/10.1161/ATVBAHA.120.314482

Chemello KV; García-Nafría J; Gallo A; Martín C; Lambert G; Blom D, 2021, 'Lipoprotein metabolism in familial hypercholesterolemia', Journal of Lipid Research, 62, http://dx.doi.org/10.1016/J.JLR.2021.100062

Chemello K; Coassin S; Khantalin I; Gieger C; Peters A; Zschocke J; Lamina C; Lambert G, 2021, 'GENOME-WIDE CHARACTERIZATION OF A HIGHLY PENETRANT FORM OF HYPERLIPOPROTEIN(A)EMIA CAUSATIVELY ASSOCIATED WITH GENETICALLY ELEVATED CARDIOVASCULAR RISK', ATHEROSCLEROSIS, 331, pp. E115 - E115

Huijgen R; Blom DJ; Hartgers ML; Chemello K; Benito-Vicente A; Uribe KB; Behardien Z; Blackhurst DM; Brice BC; Defesche JC; de Jong AG; Jooste RJ; Solomon GAE; Wolmarans KH; Hovingh GK; Martin C; Lambert G; Marais AD, 2021, 'Novel PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Variants in Patients With Familial Hypercholesterolemia From Cape Town (vol 41, 10.1161/ATVBAHA.120.314482, 2020)', ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 41, pp. E77 - E77, http://dx.doi.org/10.1161/ATV.0000000000000137

Blanchard V; Garçon D; Jaunet C; Chemello K; Billon-Crossouard S; Aguesse A; Garfa A; Famchon G; Torres A; Le May C; Pichelin M; Bigot-Corbel E; Lambert G; Cariou B; Hadjadj S; Krempf M; Bach-Ngohou K; Croyal M, 2020, 'A high-throughput mass spectrometry–based assay for large-scale profiling of circulating human apolipoproteins', Journal of Lipid Research, 61, pp. 1128 - 1139, http://dx.doi.org/10.1194/JLR.D120000835

Chemello K; Beeské S; Trang Tran TT; Blanchard V; Villard EF; Poirier B; Le Bail JC; Dargazanli G; Ho-Van-Guimbal S; Boulay D; Bergis O; Pruniaux MP; Croyal M; Janiak P; Guillot E; Lambert G, 2020, 'Lipoprotein(a) Cellular Uptake Ex Vivo and Hepatic Capture In Vivo Is Insensitive to PCSK9 Inhibition With Alirocumab', Jacc Basic to Translational Science, 5, pp. 549 - 557, http://dx.doi.org/10.1016/j.jacbts.2020.03.008

Evison BJ; Palmer JT; Lambert G; Treutlein H; Zeng J; Nativel B; Chemello K; Zhu Q; Wang J; Teng Y; Tang W; Xu Y; Rathi AK; Kumar S; Suchowerska AK; Parmar J; Dixon I; Kelly GE; Bonnar J, 2020, 'A small molecule inhibitor of PCSK9 that antagonizes LDL receptor binding via interaction with a cryptic PCSK9 binding groove', Bioorganic and Medicinal Chemistry, 28, http://dx.doi.org/10.1016/j.bmc.2020.115344

Blanchard V; Croyal M; Khantalin I; Ramin-Mangata S; Chemello K; Nativel B; Blom DJ; Marais AD; Lambert G, 2019, 'Reduced Lipoprotein(a) Associated With the Apolipoprotein E2 Genotype Confers Cardiovascular Protection in Familial Hypercholesterolemia', Jacc Basic to Translational Science, 4, pp. 425 - 427, http://dx.doi.org/10.1016/j.jacbts.2019.03.002

Chemello K; Martín C; Lambert G, 2019, 'PCSK9 inhibition for autosomal recessive hypercholesterolemia', Atherosclerosis, 284, pp. 209 - 211, http://dx.doi.org/10.1016/j.atherosclerosis.2019.02.013

Blanchard V; Khantalin I; Ramin-Mangata S; Chémello K; Nativel B; Lambert G, 2019, 'PCSK9: from biology to clinical applications', Pathology, 51, pp. 177 - 183, http://dx.doi.org/10.1016/j.pathol.2018.10.012

Croyal M; Tran TTT; Blanchard RH; Le Bail JC; Villard EF; Poirier B; Aguesse A; Billon-Crossouard S; Ramin-Mangata S; Blanchard V; Nativel B; Chemello K; Khantalin I; Thedrez A; Janiak P; Krempf M; Boixel C; Lambert G; Guillot E, 2018, 'PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate', Clinical Science, 132, pp. 1075 - 1083, http://dx.doi.org/10.1042/CS20180040

Thedrez A; Blom DJ; Ramin-Mangata S; Blanchard V; Croyal M; Chemello K; Nativel B; Pichelin M; Cariou B; Bourane S; Tang L; Farnier M; Raal FJ; Lambert G, 2018, 'Homozygous familial hypercholesterolemia patients with identical mutations variably express the LDLR (low-density lipoprotein receptor): Implications for the efficacy of evolocumab', Arteriosclerosis Thrombosis and Vascular Biology, 38, pp. 592 - 598, http://dx.doi.org/10.1161/ATVBAHA.117.310217

Blanchard V; Ramin-Mangata S; Billon-Crossouard S; Aguesse A; Durand M; Chemello K; Nativel B; Flet L; Chétiveaux M; Jacobi D; Bard JM; Ouguerram K; Lambert G; Krempf M; Croyal M, 2018, 'Kinetics of plasma apolipoprotein E isoforms by LC-MS/MS: A pilot study', Journal of Lipid Research, 59, pp. 892 - 900, http://dx.doi.org/10.1194/jlr.P083576

Benito Vicente A; Uribe KB; Chemello K; Galicia Garcia U; Alonso R; Lambert G; Martin C, 2018, 'A SYSTEMATIC FUNCTIONAL ACTIVITY CHARACTERIZATION OF THE MOST FREQUENT GOF AND LOF PSCK9 VARIANTS', ATHEROSCLEROSIS, 275, pp. E153 - E153, http://dx.doi.org/10.1016/j.atherosclerosis.2018.06.455

Chemello K; Benito Vicente A; Larrea Setubal A; Martin C; Lambert G, 2018, 'PRODUCTION AND PURIFICATION OF RECOMBINANT PCSK9 TO STUDY PCSK9 GAIN OF FUNCTION (GOF) AND LOSS OF FUNCTION (LOF) MUTANTS', ATHEROSCLEROSIS, 275, pp. E165 - E165, http://dx.doi.org/10.1016/j.atherosclerosis.2018.06.497

Conference Papers

Chemello K; Lambert G, 2022, 'Mir455 Targets the Repeated Domains of Lpa Open Reading Frame and Lowers Its Expression and The Secretion of Apolipoprotein (a) From Human Cells', in CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at Scientific Sessions of the American-Heart-Association / Resuscitation Science Symposium, IL, Chicago, 05 November 2022 - 06 November 2022

Chemello K; Gallo A; Lambert G, 2022, 'LIPOPROTEIN(A) IS A RESIDUAL CARDIOVASCULAR RISK FACTOR IN STATIN TREATED STROKE SURVIVORS: INSIGHTS FROM THE SPARCL TRIAL', in ATHEROSCLEROSIS, ELSEVIER IRELAND LTD, ITALY, Milan, pp. E28 - E28, presented at 90th Congress of the European-Atherosclerosis-Society (EAS), ITALY, Milan, 22 May 2022 - 25 May 2022

Croyal M; Wargny M; Chemello K; Chevalier C; Blanchard V; Bigot-Corbel E; Lambert G; Le May C; Hadjadj S; Cariou B, 2022, 'PLASMA APOLIPOPROTEIN CONCENTRATIONS AND NEW-ONSET DIABETES IN SUBJECTS WITH PREDIABETES', in ATHEROSCLEROSIS, ELSEVIER IRELAND LTD, ITALY, Milan, pp. E40 - E41, presented at 90th Congress of the European-Atherosclerosis-Society (EAS), ITALY, Milan, 22 May 2022 - 25 May 2022

Croyal M; Wargny M; Chemello K; Chevalier C; Blanchard V; Bigot-Corbel E; Lambert G; Le May C; Hadjadj S; Cariou B, 2022, 'PLASMA APOLIPOPROTEIN CONCENTRATIONS AND NEW-ONSET DIABETES IN SUBJECTS WITH PREDIABETES', in ATHEROSCLEROSIS, ELSEVIER IRELAND LTD, ITALY, Milan, pp. E39 - E40, presented at 90th Congress of the European-Atherosclerosis-Society (EAS), ITALY, Milan, 22 May 2022 - 25 May 2022

Chemello K; Lambert G, 2019, 'Lipoprotein (a) Cellular Uptake ex-vivo and Hepatic Capture in-vivo is Insensitive to Pcsk9 Inhibition With Alirocumab', in CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, PA, Philadelphia, presented at Scientific Sessions of the American-Heart-Association, PA, Philadelphia, 16 November 2019 - 18 November 2019

Back to profile page